New insulin copycat put to the test in healthy volunteers

This study tested whether a new rapid-acting insulin (called I004) works the same as the approved insulin NovoLog. Sixty-nine healthy volunteers each received a single dose of both insulins at different times, and researchers measured how quickly the insulin entered the blood and how it controlled blood sugar. The goal was to show the new insulin is a "biosimilar" — meaning it is highly similar to NovoLog — not to treat any disease.